POLYENG aims at developing a set of highly efficient biomolecules, alginates and other uronic acid containing biopolymers, with a wide variety of programmable properties designed for advanced drug delivery systems or as encapsulation matrix for cells. The technology is based on a unique set of recently discovered polymer modifying C-5 epimerases with capacity to introduce sites for cooperative ion binding into soluble polyuronates. Through enzymatic modification we will control the sequential structure of these polymers and thus tailor their properties essential to their use as gel matrices in pharmaceuticals drug delivery, in bioreactors, and cell therapeutic systems. POLYENG will develop these enzymes from bacteria and algae into robust tools. The epimerisation process will be optimised and the structure and functional properties of the new materials will be evaluated both on molecular bases and in applications.
Funding SchemeCSC - Cost-sharing contracts
SL1 3UH Slough
751 23 Uppsala